19 results about "Cells transplantation" patented technology

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

The present disclosure is generally directed to the use of biomaterial scaffolds engineered with SA-FasL for the transplantation of stem cell derived β-cells as a treatment for Type I diabetes. Early engraftment post-transplantation and subsequent maturation of these β-cells may be limited by the initial inflammatory response, which impacts the ability to sustain normoglycemia at long times. The survival and development of immature hPSC-derived β-cells transplanted on poly(lactide-co-glycolide) (PLG) microporous scaffolds into the peritoneal fat, a site being considered for clinical translation, was investigated. The scaffolds were modified with biotin for binding of a streptavidin-FasL (SAFasL) chimeric protein to modulate the local inflammatory microenvironment. The presence of FasL impacted infiltration of monocytes and neutrophils and altered their phenotypic response. Conditioned media generated from scaffolds explanted at day 4 did not impact hPSC-derived β-cell survival and maturation in vitro, which was not observed with unmodified scaffolds. Following transplantation, β-cell viability and differentiation were improved with SA-FasL modification. A sustained increase in insulin positive cell ratio was observed with SA-FasL modified relative to unmodified scaffolds. These results demonstrate that SA-FasL-modified scaffolds can mitigate initial inflammatory response and enhance β-cell engraftment and differentiation.

This invention discloses a method for constructing a PBMC-derived humanized mouse scleroderma model. Human peripheral blood mononuclear cells are transplanted into immunodeficient mice, and a human immune system is reconstructed in the mice. Bleomycin is injected into the local skin of the mice in a round-point manner to induce fibrosis and form a scleroderma model. This application can more comprehensively simulate the complex pathological process of immune abnormalities and tissue fibrosis coexisting in human scleroderma, and provides a more realistic and systematic experimental platform for in-depth exploration of the immune mechanism of this disease.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition for treating thalassemia and application thereof. The invention provides a pharmaceutical composition for treating thalassemia, which comprises: (a) a cell population containing a first type of cells and a second type of cells, the cell population can be used for differentiating to generate red blood cells, target loci of the first type of cells are edited to increase red blood cells expressing functional hemoglobin generated by differentiation of the cell population, and target loci of the second type of cells are edited to generate target loci of the second type of cells; the target gene loci of the second type of cells are not edited; (b) a mobilizing agent. The medicine composition can achieve the effect of treating thalassemia through cell transplantation without removing marrow, and the clinical treatment risk of a patient is reduced.

The invention provides a leukemia cell strain induced by an AVEN-NUTM1 fusion gene as well as an establishment method and application of the leukemia cell strain. The leukemia cell strain can stably express the AVEN-NUTM1 fusion gene, can be subcultured in vitro for a long time and maintain the multiplication capacity, and can induce leukemia after being transplanted into a receptor animal. The establishment method comprises the following steps: infecting hematopoietic stem / progenitor cells by using a virus vector carrying an AVEN-NUTM1 fusion gene, transplanting the infected cells into a receptor mouse body to induce leukemia, separating leukemia cells from the diseased mouse body, and culturing in vitro to finally obtain the stable cell strain. The cell strain established by the invention fills the blank of lack of stable and reliable experimental models in the research field of NUTM1 related leukemia, and provides a key tool and platform for analyzing pathogenesis of the leukemia, screening therapeutic drugs and developing new therapeutic strategies.

The invention discloses a fibroblast tumor cell related to skin-derived acute lymphocytic leukemia and application of the fibroblast tumor cell, and belongs to the technical field of biomedicine, and the cell is derived from a skin tissue microenvironment in a human leukemia cell transplantation nude mouse leukemia model. The cell name is mouse acute lymphocytic leukemia related fibroblast tumor cell HXLAF-HS, the preservation number is CCTCC NO: C2023341, the preservation date is December 7, 2023, and the preservation unit is China Center for Type Culture Collection. The HXLAF-HS cell provided by the invention can provide guidance for related pathogenesis of acute lymphocytic leukemia, new treatment schemes, preclinical evaluation of new drugs and the like, and has relatively high clinical application value.

Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.

A nucleic acid encoding human frataxin protein, a gene therapy vector including the nucleic acid, and genetically modified cells containing the nucleic acid or the vector are disclosed. The encoded human frataxin protein includes upstream cell secretion and cell penetration peptides. The genetically modified cells may be used in a method of treating Friedreich's Ataxia by transplanting a cell genetically modified by a gene therapy vector including the nucleic acid encoding human frataxin protein into a patient.

Provided herein are methods of producing engineered target organs (e.g., a pancreas) and / or cells therefrom (e.g., islets) using a non-human mammal host. In some embodiments, the methods relate to injecting hypoimmunogenic human pluripotent stem cells (HIP-hPSC) into a blastocyst of a surrogate non-human mammal to produce a chimeric blastocyst and implanting the chimeric blastocyst into the uterus of the surrogate non-human mammal, wherein after implantation the chimeric blastocyst develops into a non-human mammal host comprising a target organ with chimeric contribution from the HIP-hPSCs. In further embodiments, the target organ and / or cells therefrom are transplanted into a human subject having a disease or condition. In some embodiments, the HIP-hPSCs comprise one or more modifications that reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors.

The present application belongs to the technical field of animal model construction, and aims at the problem of the lack of human hepatic stellate cells leading to the liver fibrosis animal model, and provides a construction method and application of a liver fibrosis mouse model based on a human hepatic stellate cell strain.The present application uses an immunodeficient mouse as an animal model, uses luciferase and red fluorescent protein labeled LX-2, and injects MCT into the abdominal cavity to make a liver injury model of the mouse, injects LX-2 into the spleen after liver injury, transplants human LX-2 cells into the NSG mouse, and then injects CCl4 into the abdominal cavity of the mouse.Through the method, the implantation, distribution, proliferation and liver fibrosis of the transplanted LX-2 in the liver are successfully studied.The model is suitable for human in-vivo experiments of biological treatment and drug treatment and other treatment methods targeting hepatic stellate cells or fibroblasts.

This invention discloses a 3D scaffold for repairing defective lung injury, its construction method, and its applications, belonging to the field of biomedical materials and tissue engineering technology. This invention uses cationic polysaccharide chitosan and polymer γ-polyglutamic acid as raw materials, utilizing their electrostatic interaction to achieve cross-linking without cross-linking agents, and combines this with freeze-drying technology to prepare a three-dimensional spherical γ-PGA / CS composite scaffold. The above composite scaffold is combined with bone marrow stem cell exosomes (MSC-Exos) and type II alveolar epithelial cells (RLE-6TN). By loading exosomes onto the scaffold and implanting lung cells, local enrichment and targeted delivery are achieved, solving the problems of poor targeting of bone marrow stem cell exosomes and easy loss during transplantation of individual cells. This functional scaffold can accelerate lung function recovery by regulating the inflammatory microenvironment at the site of lung injury in SD rats, promoting lung cell regeneration, and reducing secondary lung tissue damage. It provides a novel implantable, minimally invasive treatment for defective lung injury-related diseases, possessing good clinical translational potential and application prospects in organ damage repair.

Polycaprolactone (PCL) scaffolds having macropores interconnected with micorpores are provided. Tissue grafts that include the PCL scaffold having therapeutic cells encapsulated within the macropores are also provided. Also provided are methods of making the PCL scaffold and the tissue graft, and methods of transplanting cells into an individual using the tissue graft.

The disclosure provides, in various embodiments, non-human animals that comprise a human immune cell engraftment and / or functional human immune system. The disclosure also provides, in various embodiments, methods of generating said non-human animals. The disclosure also provides, in various embodiments, methods of determining immunogenicity of antigens or an immunogenic fragment thereof or antigenic therapies and / or identifying agents that modulate immune response.

This invention provides a non-human vertebrate exhibiting a higher human liver cell growth rate, a higher human liver cell replacement rate, and higher histological-physiological human reproducibility than existing non-human vertebrates comprising the human liver transplanted therein and a method for producing such non-human vertebrate. Specifically, the method for producing a transgenic non-human vertebrate comprising human liver cells transplanted therein comprises transplanting human liver cells in a non-human vertebrate that has impaired or lowered immune reactions against humans in the presence of human IL-6 in vivo.

The present invention relates to a pharmaceutical composition comprising hyaluronic acid or a salt thereof, the molecular weight of which is greater than 2 MDa, and at least 8 amino acids which are essential for humans, selected from the group consisting of lysine, valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, threonine and histidine. The invention also relates to uses of the pharmaceutical composition for improving wound healing, for hydrating healthy tissue and / or a wound, for improving cell viability, for improving cartilage and / or joint regeneration, or for improving tissue or cell grafting and / or transplantation.

The application discloses a method and application of targeting knockout of a pig TXLNB gene locus, and belongs to the technical field of gene editing engineering. The application designs a TXLNB gene knockout method based on a CRISPR / Cas9 system. Specifically, by screening gRNA target points and gRNA combinations, it is found that when the two ends of a targeted TXLNB exon 3 are adopted, a specific gRNA combination can realize efficient TXLNB gene deletion. After the related gene fragments in pig fibroblasts are deleted by the method, the animal model formed by transplanting the knockout cells into a small pig in vivo has obvious phenotypes, and has great potential in pig breeding related research.

The present application relates to the field of biotechnology, and relates to immune monitoring and imaging, and particularly discloses a molecular glue-gated ectopic thymus model and a preparation and evaluation method thereof, the ectopic thymus model comprising engineered cells expressing NOX2 complex on the surface, T cell surface death receptor FAS, and humanized CRBN protein in the cell; the engineered cells are used for targeted degradation of transcription factors by reaction of a molecular glue drug with the CRBN protein, and for inhibition of type I interferon synthesis and inflammatory storm. The engineered cells constructed in the present application are transplanted into developed organoids, which can be regulated by a molecular glue drug, avoiding problems such as uncontrollable gene silencing and inflammatory storm caused by traditional organoids, and can maintain the effect for a long time. Based on expansion microscopy and methods such as nucleic acid, protein and lipid imaging, the present application can realize quantitative analysis of the drug action mechanism at the molecular level in the cell, which is beneficial to effect monitoring and related immune mechanism analysis and drug development.

Method for producing a spontaneous metastasis model is disclosed herein. The models, according to various embodiments herein, achieve a higher metastasis incidence rate, in an instance about 100% for mesenteric lymph node (mLN) invasion and about 80 to 90% for secondary organs. The models are kinetic model having a luciferase-based expression system that provide more statistically significant and robust data. The embodiments herein further include a method for producing the model for metastasis, comprising transplanting recombinant carcinoma cells having increased invasiveness and decreased tumorigenic properties and luciferase gene expression system, in one or more orthotopic positions in an animal.